LifeStance Health Group, Inc. (LFST)
| Market Cap | 4.80B +135.8% |
| Revenue (ttm) | 1.58B +20.4% |
| Net Income | 50.60M |
| EPS | 0.13 |
| Shares Out | 382.15M |
| PE Ratio | 97.41 |
| Forward PE | 67.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,044,574 |
| Open | 12.69 |
| Previous Close | 12.67 |
| Day's Range | 12.52 - 12.91 |
| 52-Week Range | 4.77 - 13.56 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 14.20 (+13.15%) |
| Est. Earnings | Nov 5, 2026 |
About LFST
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic str... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LFST stock is "Buy." The 12-month stock price target is $14.2, which is an increase of 13.15% from the latest price.
News
LifeStance Health Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Outpatient mental health remains fragmented, but the organization leads with a national footprint and strong clinician growth. Productivity and revenue gains are driven by AI, operational improvements, and expanding specialty services. Margin expansion, new EHR adoption, and disciplined capital allocation support sustained mid-teens growth.
LifeStance Health Group Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Revenue and Adjusted EBITDA saw strong double-digit growth, prompting raised full-year guidance. Specialty services, especially in neuropsychological testing and treatment-resistant depression, are expanding rapidly. Productivity and retention improvements, technology investments, and a robust payer strategy support long-term growth and margin expansion.
LifeStance price target raised to $15 from $13 at Barclays
Barclays raised the firm’s price target on LifeStance (LFST) to $15 from $13 and keeps an Overweight rating on the shares. The company’s share offering continues to reduce the private…
LifeStance Health Group Announces Pricing of Secondary Public Offering
SCOTTSDALE, Ariz., Sept. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpa...
LifeStance announces 22.25M share offering of common stock for holders
LifeStance (LFST) Health Group announced that pursuant to a shelf registration statement filed with the SEC, certain stockholders of the company intend to offer 22.25M shares of LifeStance’s common st...
LifeStance price target raised to $15 from $13 at Canaccord
Canaccord raised the firm’s price target on LifeStance (LFST) to $15 from $13 and keeps a Buy rating on the shares. The firm updated its model after meeting with management…
LifeStance Health Group Announces Launch of Secondary Public Offering
SCOTTSDALE, Ariz., Sept. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpa...
LifeStance to Present at Upcoming Investor Conferences
SCOTTSDALE, Ariz., Sept. 01, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced that manageme...
LifeStance price target raised to $19 from $16 at BTIG
BTIG raised the firm’s price target on LifeStance (LFST) to $19 from $16 and keeps a Buy rating on the shares as part of a broader research note on Healthcare…
LifeStance price target raised to $13 from $9 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on LifeStance (LFST) to $13 from $9 and keeps a Neutral rating on the shares.
LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care
One in Three Women Don't Know Perimenopause Can Cause Anxiety, Depression and Mood Changes; Majority Who Seek Mental Healthcare Find It Helpful SCOTTSDALE, Ariz., Aug. 11, 2026 /PRNewswire/ -- A Life...
LifeStance price target raised to $13 from $10 at Morgan Stanley
Morgan Stanley raised the firm’s price target on LifeStance (LFST) to $13 from $10 and keeps an Overweight rating on the shares.
LifeStance price target raised to $13 from $10 at BMO Capital
BMO Capital raised the firm’s price target on LifeStance (LFST) to $13 from $10 and keeps an Outperform rating on the shares.
LifeStance price target raised to $16 from $15 at BTIG
BTIG raised the firm’s price target on LifeStance (LFST) to $16 from $15 and keeps a Buy rating on the shares. LifeStance delivered an excellent Q2 with strong growth across…
LifeStance Health Group Earnings Call Transcript: Q2 2026
Revenue grew 26% year-over-year to $435 million, with adjusted EBITDA up 94% and margins exceeding 15%. Full-year guidance was raised across all metrics, driven by strong clinician growth, productivity, and specialty services expansion. Financial flexibility supports ongoing investments and share repurchases.
LifeStance Health Group Earnings release: Q2 2026
LifeStance Health Group released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
LifeStance Health Group Slides: Q2 2026
LifeStance Health Group has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
LifeStance Health Group Quarterly report: Q2 2026
LifeStance Health Group has published its Q2 2026 quarterly earnings report on August 6, 2026.
LifeStance reports Q2 EPS 6c, consensus 8c
Reports Q2 revenue $435.4M, consensus $414.53M. “This was an outstanding second quarter and first half of 2026 for LifeStance (LFST), as we delivered quarterly revenue growth of 26%, positive net…
LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial resu...
LifeStance price target raised to $15 from $12 at BTIG
BTIG raised the firm’s price target on LifeStance (LFST) to $15 from $12 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
LifeStance price target raised to $13 from $11 at Canaccord
Canaccord raised the firm’s price target on LifeStance (LFST) to $13 from $11 and keeps a Buy rating on the shares. The firm updated its model heading into the earnings…
LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
SCOTTSDALE, Ariz., July 16, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, will issue its second quarter ...
LifeStance price target raised to $13 from $9 at Barclays
Barclays raised the firm’s price target on LifeStance (LFST) to $13 from $9 and keeps an Overweight rating on the shares. The firm expects the company to report “strong” Q2…